MET activation has been shown to compensate for inhibition of mutant EGFR, or ALK, ROS1, and RET fusion oncogenes; MET inhibition is beneficial to overcome resistance in NSCLC [249,250]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.